Shanghai JMT-Bio
Subsidiary of CSPC Pharmaceutical Group (1093)
Assets
(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EGFRMonoclonal antibody | Non-Small Cell Lung CancerColorectal Cancer | |
| Phase 3 | TSLPMonoclonal antibody | Chronic Obstructive Pulmonary DiseaseAsthma | |
| Phase 1/2 | β-Klotho (KLB)Monoclonal antibody | Cardiovascular Disease / Dyslipidemia Hypertriglyceridemia | |
| Phase 1/2 | PD-1 and IL-15 receptorProtein / enzyme therapeutic | Non-Small Cell Lung Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
24 September 2026Topline resultJMT101 (becotatug)Phase 3 of becotatug plus osimertinib in EGFR exon 20 insertion NSCLC (NCT06380348) met its PFS primary endpoint at interim
CSPC Pharmaceutical Group Limited · Source ↗
Financial reports
No financial reports recorded.